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The Cdk7/cyclin H/me´nage-a`-trois 1 (MAT1)
heterotrimer has proposed functions in tran-
scription as the kinase component of basal tran-
scription factor TFIIH and is activated in adult
hearts by Gq-, calcineurin-, and biomechanical
stress-dependent pathways for hypertrophic
growth. Using cardiac-specific Cre, we have
ablatedMAT1 in myocardium. Despite reduced
Cdk7 activity, MAT1-deficient hearts grew nor-
mally, but fatal heart failure ensued at 6–8
weeks. By microarray profiling, quantitative
RT-PCR, and western blotting at 4 weeks, genes
for energy metabolism were found to be sup-
pressed selectively, including targets of peroxi-
some proliferator-activated receptor g coacti-
vator 1 (PGC-1). Cardiac metabolic defects
were substantiated in isolated perfused hearts
and isolated mitochondria. In culture, deleting
MAT1 with Cre disrupted PGC-1 function:
PGC-1a failed to activate PGC-1-responsive
promoters and nuclear receptors, GAL4-PGC-
1a was functionally defective, and PGC-1b
was likewise deficient. PGC-1 bound to both
MAT1 and Cdk7 in coprecipitation assays. Thus,
we demonstrate a requirement for MAT1 in theCell Moperation of PGC-1 coactivators that control
cell metabolism.
INTRODUCTION
Cyclin-dependent kinases (Cdks), a family of Ser/Thr ki-
nases that require cyclin binding for activation, are subdi-
vided into two distinct groups based on their controlling
cell-cycle progression versus transcription. In mammalian
cells, at least four different Cdks (Cdk1, -2, -4, and -6) con-
tribute directly to cell cycling, activated sequentially via al-
tered levels of their respective cyclins (A1, A2, B1, B2, D1–
3, E1, and E2) (Murray, 2004). Others, such as Cdk8, -9,
and -11, are not directly involved in cell-cycle progression,
and their cyclin partners are expressed in all phases of the
cell cycle (C, T1, T2a, T2b, K, and L). These Cdks regulate
transcription, phosphorylating the C-terminal domain
(CTD) of Rpb1, the largest subunit of RNA polymerase II
(RNAPII). The CTD comprises a highly multimerized tan-
dem repeat of seven amino acids (Tyr1-Ser2-Pro3-Thr4-
Ser5-Pro6-Ser7), whose phosphorylation at Ser2 and
Ser5 is modified precisely as RNAPII translocates along
genes (Phatnani and Greenleaf, 2006). By chromatin im-
munoprecipitation, CTD phosphorylation at Ser5 is de-
tected when RNAPII is located near promoters, but not
in the 30 region of transcribed genes; conversely, Ser2-
phosphorylated RNAPII is localized preferentially 30 to
the promoter-proximal region. Among other functions,
CTD phosphorylation plays a critical role in couplingetabolism 5, 129–142, February 2007 ª2007 Elsevier Inc. 129
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abundance of these phosphorylated forms changes dra-
matically in development and pathobiology. In the heart,
CTD phosphorylation is highest in the embryo and de-
creases after birth but increases in response to bio-
mechanical, ligand-dependent, and genetic signals for
hypertrophic growth (Sano et al., 2002, 2004).
Alone among the Cdks, Cdk7 belongs to both classes
(Larochelle et al., 2006). Cdk7 and its partner, cyclin H,
were originally isolated as Cdk-activating kinase (CAK),
which is required for full activation of conventional Cdks,
phosphorylating a conserved Thr in the T loop. A third sub-
unit, me´nage-a`-trois 1 (MAT1), acts as an assembly factor,
stabilizing the complex. Cdk7/cyclin H/MAT1 was also
found to be a component of general transcription factor
TFIIH, MAT1 bridging the kinase to other components
and conferring preference for the CTD as substrate
(Rossignol et al., 1997; Zurita and Merino, 2003). Cdk7 is
believed to be responsible for CTD phosphorylation on
Ser5, the step implicated in recruiting capping enzymes
to ‘‘stalled’’ RNAPII, shortly after transcription initiation.
However, it has not been settled whether the transcrip-
tional functions of the Cdk7/cyclin H/MAT1 complex are
invariably global or potentially more selective (Larochelle
et al., 2006). In budding yeast, the Cdk7 ortholog Kin28
is required for CTD phosphorylation and indispensable
for nearly all RNAPII-mediated transcription (Holstege
et al., 1998), yet a conditional mutant of the MAT1 ortholog
TFB3 affects only a few percent of genes (Jona et al.,
2002). In fission yeast, the Cdk7 ortholog Mcs6 likewise
operates as a CTD kinase, but temperature-sensitive mu-
tations of Mcs6 or the MAT1 ortholog Pmh1 disrupt only
5% of transcripts, with overlapping effects (Lee et al.,
2005). Analogous complexities exist in metazoans. In
Drosophila melanogaster, dominant-negative Cdk7 de-
lays the onset of zygotic transcription (Leclerc et al.,
2000), but the defects from temperature-sensitive and
null alleles are limited to lower-than-normal activation of
heat-shock genes (Schwartz et al., 2003). Many technical
issues complicate such studies, including potential resid-
ual function of temperature-sensitive mutations and
potential promiscuity of dominant-negative ones.
Among the components of the Cdk7/cyclin H/MAT1
complex, only MAT1 has been ablated in mice (Rossi
et al., 2001). Germline deletion is embryonic lethal before
gastrulation, with mitotic lineages unable to proliferate and
survive. Trophoblast giant cells show reduced CTD phos-
phorylation at both Ser5 (the preferred target of Cdk7) and
Ser2 (the preferred target of Cdk9). Nevertheless, de novo
transcription, measured with a microinjected reporter
plasmid, is unimpeded by lack of MAT1. Conditional dele-
tion of ‘‘floxed’’ MAT1 alleles with Krox-20-Cre has sub-
stantiated that MAT1 is essential, but its impact varies
markedly among the targeted cell types: mitotic germ
cells die rapidly, whereas loss of MAT1 in postmitotic
Schwann cells causes a late-onset demyelinating disorder
(Korsisaari et al., 2002).
In addition to the Rpb1 CTD, TFIIH-associated Cdk7 is
now known to phosphorylate gene-specific transcrip-130 Cell Metabolism 5, 129–142, February 2007 ª2007 Elseviertional regulators including nuclear receptors (Keriel et al.,
2002; Compe et al., 2005; Larochelle et al., 2006). Muta-
tions in the XPD helicase subunit of TFIIH interfere with
Cdk7 function, ascribed to a structural role in positioning
the kinase relative to its substrates (Keriel et al., 2002).
TFIIH regulates the activity of multiple nuclear hormone
receptors, phosphorylating the AF-1 activation domain in
the retinoic acid and estrogen receptors (RARa, ERa)
(Keriel et al., 2002), playing a similar role for PPARa and
g (Compe et al., 2005), and phosphorylating a partner of
the vitamin D receptor (Drane´ et al., 2004).
Cdk7/cyclin H/MAT1 and Cdk9/cyclin T both become
activated in human heart failure and in mice with chronic
cardiac hypertrophy (Sano et al., 2002, 2004). Pathophys-
iological levels of Cdk9 activity cause myocyte enlarge-
ment and predispose cardiac muscle to apoptosis, re-
pressing the transcription of PGC-1a (Sano et al., 2004),
an essential coactivator for mitochondrial energy metabo-
lism (Puigserver and Spiegelman, 2003; Kelly and Scar-
pulla, 2004; Spiegelman and Heinrich, 2004; Arany et al.,
2005; Leone et al., 2005; Sano and Schneider, 2005).
The critical importance of downregulating PGC-1a in sen-
sitizing heart muscle to stress is highlighted by the accel-
erated development of heart failure in mice lacking this
protein (Arany et al., 2006).
Thus far, potential functions of the Cdk7 heterotrimer in
the heart had yet to be demonstrated. By cardiac-specific
deletion of MAT1, we found that loss of MAT1 and the
ensuing loss of TFIIH-associated Cdk7 activity result in a
late-onset metabolic cardiomyopathy. We identified a
block to the functional activity of PGC-1a and PGC-1b in
MAT1-deficient cells and showed that PGC-1 interacts
physically with MAT1 and Cdk7. This block to metabolic
gene expression via defective operation of the PGC-1
family implicates MAT1 in the control of cardiac metabo-
lism, with deficient coactivation by PGC-1 the responsible
molecular event.
RESULTS
MAT1 Is Dispensable for Myocardial Growth
MAT1F/F mice (Korsisaari et al., 2002) were bred with mice
expressing Cre recombinase under the control of the car-
diomyocyte-specific a-myosin heavy chain (aMHC) pro-
moter (Gaussin et al., 2002) and back-bred to MAT1F/F
mice to generate the cardiac-specific knockout (aMHC-
Cre+/0;MAT1F/F; CKO; Figures 1A and 1B). Control mice
were aMHC-Cre+/0;MAT1F/+ littermates, differing by the
presence of one wild-type MAT1 allele and excluding
Cre-mediated toxicity as a basis for phenotypic disparity.
In contrast to its readily visualized expression in control
cardiomyocytes (and cardiac nonmuscle cells of both ge-
notypes), MAT1 was not detected by immunostaining in
CKO myocytes (Figure 1C). In purified cardiomyocytes,
R90% of MAT1 protein was eliminated (Figure 1D). Resid-
ual cardiac MAT1 was chiefly attributable to noncardio-
myocytes lacking the recombinase. In the absence of
MAT1, Cdk7 activity was reduced, as measured as total
Cdk7 activity or, most markedly, Cdk7 activity physicallyInc.
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(Figure 1E). As with germline deletion of MAT1 (Rossi
et al., 2001), Cdk7 and cyclin H protein decreased sec-
ondarily in CKO myocardium, reflecting MAT1’s role as
their chaperone, without affecting other TFIIH compo-
nents (Figure 1F). aMHC-Cre elicits recombination as
early as E8.5, with near uniformity by E11.5 (Gaussin
et al., 2002). Concordant with these properties, reduction
of MAT1 protein in myocardium was evident at the earliest
stage examined (E14.5) and was maximal before birth
(Figure 1G).
Next, we tested whether MAT1 is critical for CAK func-
tion in myocardium. If so, one would expect an overtly hy-
poplastic phenotype or impaired cycling of myocytes
before cell-cycle exit occurs (MacLellan et al., 2005).
However, CKO mice were born at the expected Mendelian
frequency, with no gross cardiac anomalies in E14.5 or
newborn mice (Figure 1H) and no difference in the heart
weight/body weight ratio, ventricular diameter, trabecula-
tion, wall thickness, number of cardiomyocytes, cardio-
myocyte diameter (Figure 1I and unpublished data), or
maturational growth in the first month after birth (Figure 2).
Likewise, we observed no change in cell-cycle-regulated
cyclins, expression and activity of Cdks, T loop phosphor-
ylation of Cdk2 and Cdc2, phosphorylation of Rb (a sub-
strate of G1 Cdks), expression of proliferating cell nuclear
antigen (PCNA, a marker of cycling; Figure 1G), or staining
for Ser10-phosphorylated histone H3 (H3P, a marker of
Cdc2 activity in mitosis; control, 0.67% ± 0.03%; CKO,
0.60% ± 0.05%; Figure 1I). This concurs with prior evi-
dence indicating that MAT1 is dispensable for Cdk activa-
tion by Cdk7. In addition, no gross defect was seen in
RNAPII phosphorylation, even using antibody specific
for the Ser5 phosphoepitope (Figure 1G).
Cardiac-Specific Loss of MAT1 Causes
Lethal Cardiomyopathy
As assessed by gated magnetic resonance imaging, ven-
tricular geometry and function were unaffected at 3 weeks
(unpublished data), but heart-specific ablation ofMAT1 in-
evitably caused later heart failure (Figures 2A–2F). At 5–6
weeks, CKO mice showed decreased movement and sys-
temic edema (Figure 2A). Though myocyte enlargement
and fibrosis were still minimal at this age (Figure 2B),
loss of MAT1 already resulted in cardiomyocyte apoptosis
(Figure 2C; control, < 0.01%; CKO, 0.8%; p < 0.001). Ap-
optosis was confirmed by immunoblotting for activated
(cleaved) caspase-3 and cleavage of poly(ADP-ribose)
polymerase (PARP), a caspase-3 substrate (Figure 2D).
By 6 weeks, Doppler and M-mode echocardiography
demonstrated severe systolic dysfunction (peak aortic
ejection velocity, 65.1 ± 8.9 versus 101.5 ± 3.4 cm/s in
controls; fractional shortening, 13% ± 4% versus 39% ±
3% in controls; n = 6; p < 0.05). Impaired systolic function
was confirmed by gated magnetic resonance imaging
(end-systolic volume, 34.0 ± 2.4 versus 19.7 ± 2.4 ml in
controls; fractional shortening, 14.0% ± 9.6% versus
44.3% ± 9.6% in controls; n = 2; p = 0.05). All MAT1-defi-
cient mice died by 8 weeks of age (Figure 2E). DefectiveCell Mventricular function was substantiated in isolated mouse
hearts, even at 4 weeks (when baseline pump function
was still preserved), using the provocable conditions
of calcium-induced inotropy (Figure 2G; see also Table
S1 in the Supplemental Data available with this article
online).
Next, we tested whether heart failure in MAT1 CKO
mice was caused by a primary loss of MAT1 versus the
concomitant secondary defects in Cdk7/cyclin H levels
(compare Figures 1E and 1F). Transgenes individually ex-
pressing MAT1, Cdk7, or cyclin H via the aMHC promoter
failed to increase Cdk7 activity significantly in the wild-
type background and evoked no detectable phenotype;
in contrast, marked elevation of Cdk7 activity resulted
from combined expression of Cdk7 plus its cyclin (Fig-
ure S1A). Thus, no single component was limiting under
normal conditions. To increase Cdk7 activity in myocar-
dium, we then crossbred these transgenic lines to create
double (Cdk7/cyclin H) and triple (Cdk7/cyclin H/MAT1)
transgenic mice. All were morphologically identical to
control littermates at birth and grew normally. As ex-
pected, cardiac-specific MAT1 rescued the lethal pheno-
type in cardiac CKO mice (aMHC-Cre+/0;MAT1F/F;aMHC-
MAT1+/0), including XPB-associated CTD kinase activity,
ventricular wall thinning, and dilatation, prolonging sur-
vival of the animals despite ablation of the endogenous
MAT1 gene (Figures 2E and 2F; Figure S1B). Cdk7/cyclin
H had no such effect, even though it was sufficient to re-
store Cdk7 activity directed at Cdk2 (Figures 2E and 2F;
Figure S1C). These results are consistent with in vitro re-
ports that MAT1 switches the substrate specificity of the
Cdk7/cyclin H complex to favor the RNAPII CTD over
Cdk2 (Rossignol et al., 1997) and—together with the find-
ings presented in Figures 1G–1I—suggest that the princi-
pal functions of MAT1 in myocardium more likely involve
a role in Cdk7-dependent transcription than in Cdk7-
dependent cycling. An absolute requirement for MAT1 to
rescue Cdk7 activity associated with the XPD subunit of
TFIIH confirms that MAT1 in the intact heart anchors
Cdk7/cyclin H to the core TFIIH complex.
Deletion of MAT1 Causes Cardiac Metabolic
Dysfunction
Given the normal properties of MAT1-deficient hearts in
the first weeks of life, we postulated that key functions
of MAT1 might reasonably pertain to a more selective
role than transcription of all genes. Using genome-wide
microarray analysis of ventricular myocardium at 2 weeks,
no obviously important or suggestive changes were
detected. By 4 weeks, however, extensive changes
emerged. Notably, a cluster of genes for mitochondrial
metabolic enzymes—comprising b-oxidation of fatty
acids, the tricarboxylic acid cycle, and respiratory chain
complexes—was globally downregulated in MAT1 CKO
myocardium (Gene Ontology cluster GO:0008152; p <
105). Real-time quantitative RT-PCR was then performed
to confirm the downregulation of cardiac metabolic genes
(Acadm, Atp5a1, Atp5b, Atp5c1, Atp5g1, Coq7, Cox5a,
Cox6a2, Cox7a2I, Cpt1b, Cycs, Esrra, Ppargc1a,etabolism 5, 129–142, February 2007 ª2007 Elsevier Inc. 131
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MAT1 Is Required for Transactivation by PGC-1Figure 1. Deletion ofMAT1 in Myocardium Disrupts Cdk7 Activity, but Not Cardiac Growth, CAK Activity, or CTD Phosphorylation
(A) PCR genotyping of myocardial DNA, showing conditional deletion of floxed MAT1 contingent on coinheritance of aMHC-Cre.
(B) MAT1 protein was deleted specifically from myocardium (left), not other organs (right). Total actin is shown for comparison.
(C) MAT1 protein in ventricular myocardium was deleted from myocytes specifically (MF20-positive, circled) and persisted in cardiac nonmuscle cells
(MF20-negative, arrowhead).
(D) Western blot showing loss of MAT1 specifically in purified cardiomyocytes, but not cardiac nonmyocytes.
(E) Disruption of total and TFIIH-associated Cdk7 activity in myocardium by conditional deletion of MAT1. Complexes were immunoprecipitated with
antibody to Cdk7 (upper panel) or the TFIIH subunit XPB (lower panel). Cdk7 activity was determined by an immunocomplex kinase assay using
GST-CTD as substrate.
(F) Loss of MAT1 caused secondary defects in Cdk7 and cyclin H protein levels.132 Cell Metabolism 5, 129–142, February 2007 ª2007 Elsevier Inc.
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MAT1 Is Required for Transactivation by PGC-1Ppargc1b, Sdha, Slc25a4, Sod2, and Uqcrc1; Table 1).
Further loss of Ppargc1a, Ppargc1b, and Esrra was seen
between 4 and 5 weeks of age (Figure S2).
As seen by transmission electron microscopy, abnor-
mal mitochondria were already scattered among the intact
ones at 3 weeks, whereas myofibrils were properly aligned
(G) Above: western blots showing that deletion of MAT1 fails to affect RNAPII phosphorylation or cell-cycle-regulated proteins grossly, and immu-
nocomplex kinase assays showing progressive loss of Cdk7 activity, sparing Cdk9. Below: deletion ofMAT1 did not impair phosphorylation or activity
of Cdk2 and Cdc2. Age was 6 weeks in (A)–(G) unless otherwise specified.
(H) Cardiac morphology was unchanged. Scale bars: E14.5 = 0.2 mm; newborn = 0.5 mm; d14 = 2 mm.
(I) Deletion of MAT1 did not alter the prevalence of mitotic cardiomyocytes in newborn mice (left), myocyte enlargement after birth (middle), or the
heart-to-body weight ratio (right). In this and all other figures, error bars denote SEM.
Figure 2. Deletion of MAT1 in Myocardium Causes Lethal Cardiomyopathy
(A) Severe systemic edema indicative of heart failure in MAT1 CKO mice at 6 weeks of age.
(B) Loss of MAT1 causes chamber dilatation (Ba and Bb), increased myocyte diameter (Bc and Bd; hematoxylin and eosin staining), and mild fibrosis
(Be and Bf; Gomori’s trichrome stain). (Ba), (Bc), and (Be), control; (Bb), (Bd), and (Bf), CKO. Scale bars: (Ba) and (Bb) = 2 mm; (Bc)–(Bf) = 20 mm.
(C) Loss of MAT1 causes cardiomyocyte apoptosis. See Results for quantitation.
(D) Loss of MAT1 causes caspase-3 activation and PARP cleavage.
(E and F) Transgenic rescue of lethal cardiomyopathy by forced expression of MAT1.
(E) aMHC-MAT1 prevented the early mortality caused by cardiac-specific deletion of MAT1; aMHC-Cdk7 plus aMHC-cyclin H did not. nR 5 for each
genotype.
(F) Short-axis cross-sections of perfusion-fixed hearts showing prevention of ventricular remodeling. Scale bar = 1 mm.
(G) Impaired contractile responses to Ca2+ in isolated mouse heart (age 4 weeks). Left, LV systolic and diastolic pressure; center, dp/dtmax and
dp/dtmin; right, rate-pressure product. Control, n = 6; MAT1 CKO, n = 3; *p < 0.05 for MAT1 CKO versus control mice; yp < 0.05 for 4 versus
2 mM Ca2+. Individual and group data are shown. See also Table S1.Cell Metabolism 5, 129–142, February 2007 ª2007 Elsevier Inc. 133
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Symbol Name 2 Weeks 4 Weeks
Atp5c1 ATP synthase, H+ transporting, mitochondrial F0 complex, gamma polypeptide 1 0.65 0.35
Cycs cytochrome c, somatic 0.64 0.37
Coq7 dimethyl-Q7 0.81 0.40
Essra estrogen-related receptor alpha 0.87 0.51
Slc25a4 solute carrier family 25, member 4 (adenine nucleotide translocator 1, skeletal muscle) 1.03 0.51
Cox6a2 cytochrome c oxidase subunit VIa, polypeptide 2 (heart) 0.72 0.53
Uqcrc1 ubiquinol-cytochrome c reductase core protein 1 0.77 0.54
Atp5b ATP synthase, H+ transporting, mitochondrial F1 complex, beta subunit 0.76 0.55
Cox5a cytochrome c oxidase subunit Va 0.80 0.57
Atp5a1 ATP synthase, H+ transporting, mitochondrial F1 complex, alpha subunit, isoform 1 1.05 0.62
Atp5g1 ATP synthase, H+ transporting, mitochondrial F0 complex, subunit c, isoform 1 0.92 0.62
Cox7a2I cytochrome c oxidase polypeptide VIIa (heart, mitochondria) 0.93 0.63
Acadm acetyl-CoA dehydrogenase, medium chain 0.86 0.66
Sdha succinate dehydrogenase complex, subunit A, flavoprotein 0.93 0.66
Cpt1b carnitine palmitoyltransferase 1b (muscle) 0.96 0.67
Ppargc1a peroxisome proliferator-activated receptor gamma coactivator 1 alpha 0.99 0.67
Ppargc1b peroxisome proliferator-activated receptor gamma coactivator 1 beta 0.95 0.68
Sod2 superoxide dismutase 2 (mitochondria) 1.00 0.73
Ppara peroxisome proliferator-activated receptor alpha 0.98 0.94
Nrf2 nuclear respiratory factor 2 1.02 1.00
Nrf1 nuclear respiratory factor 1 1.02 1.21
Sp1 trans-acting transcription factor 1 1.11 1.18
Ventricular transcript levels for each genotype were determined by real-time qRT-PCR and normalized to GAPDH. Results shown
are the ratios of gene expression in MAT1 CKO mice relative to age-matched littermate controls (n = 6). Repression (% 0.75) is
italicized; p < 0.05.(Figure 3A). In 4-week-old CKO hearts, mitochondria were
severely abnormal, and myofibrils were poorly organized
at this later stage. Consistent with the impairments in
gene expression, we confirmed downregulation of ATP
synthase b, the adenine nucleotide translocator, and cyto-
chrome oxidase Va (Figure 3B) and reduced enzyme ac-
tivities of tricarboxylic acid cycle and respiratory chain
complexes (Table S2). In Langendorff-perfused hearts,
oleate and glucose oxidation were reduced by at least
60% and 50%, respectively (Figure 3C). Likewise, state
III respiration and the respiratory control ratio were re-
duced in mitochondria from MAT1-deficient hearts, with
little change in ADP/O (Figure 3D). As expected for a
heart-specific knockout, no defect was seen in liver mito-
chondria. Thus, cardiac mitochondrial dysfunction pre-
cedes and may plausibly contribute to the rapid deteri-
oration of cardiac pump function in MAT1 CKO mice.
Mitochondrial DNA content was unaffected, as assessed
by Southern blotting and quantitative PCR (data not
shown). Similar findings—decreased PGC-1a, mitochon-
drial enzyme activities, and oxidative capacity, but not
mitochondrial replication—have been reported in experi-134 Cell Metabolism 5, 129–142, February 2007 ª2007 Elseviermental heart failure (Garnier et al., 2003). Hence, it was es-
sential to prove direct effects of MAT1 on PGC-1 and its
targets.
Loss of MAT1 Disrupts PGC-1-Dependent
Transcription
In addition to its role as a CTD kinase, Cdk7 has a modula-
tory role in transcription, phosphorylating nuclear recep-
tors (Keriel et al., 2002; Compe et al., 2005), an associated
protein (Drane´ et al., 2004), and other factors (Larochelle
et al., 2006). To test a selective requirement for MAT1 in
specific subsets of genes, we first confirmed that a proven
targetof MAT1 wasdisrupted—ligand-dependent transac-
tivation of RARa (Keriel et al., 2002). Wild-type andMAT1F/F
mouse embryonic fibroblasts (MEFs) were transduced with
Cre virus and then with a RARa expression vector, its part-
ner RXRa, and a RAR-responsive reporter. In wild-type
cells, 106 M all-trans retinoic acid increased RARa activity
17-fold at 24 hr; in contrast, the response in MAT1-
depleted cells was only 60% of the control response
(Figure 4A). Deleting MAT1 did not affect irrelevant control
promoters (Fos, Hsp70/Hspa1b, and CMV; Figure 4B).Inc.
Cell Metabolism
MAT1 Is Required for Transactivation by PGC-1Figure 3. Mitochondrial and Metabolic Abnormalities in MAT1-Deficient Hearts
(A) Abnormal mitochondria in myocardium of MAT1 CKO mice as early as 3 weeks. Scale bars: (Aa), (Ab), (Ae), and (Af) = 2 mm; (Ac), (Ad), (Ag), and
(Ah) = 0.5 mm. Arrowhead, normal mitochondrion with densely packed cristae; asterisk, abnormal mitochondrion with irregular, deficient cristae.
(B) Reduced expression of proteins of mitochondrial energy metabolism in hearts of MAT1 CKO mice at 4 weeks of age.
(C) Langendorff-perfused heart studies at 3.5 weeks of age. Oleate and glucose oxidation were reduced in MAT1-deficient hearts. Control, n = 11;
CKO, n = 5; *p < 0.05.
(D) State III and IV respiration, respiratory control ratio (RCR), and ADP/O were analyzed in isolated mitochondria from control and MAT1-deficient
hearts (age 3.5 weeks). Results shown are for 5 mM succinate as substrate or 5 mM glutamate plus 5 mM malate. n = 5; *p < 0.05.Thus, no global defect was provoked. Since the CMV
reporter is especially robust, these results also exclude
a general lack of competence for high-level transcription.
Based on microarray findings,ultrastructure,RT-PCR re-
sults, enzyme levels, and enzyme activities, we speculated
that TFIIH-associated Cdk7 activity selectively modulates
nuclear genes encoding mitochondrial proteins for energy
metabolism. This ensemble is coordinately regulated by
the transcriptional coactivator PGC-1, working through
nuclear receptors (PPARa/b/g/d; ERRa/b) and other DNA-
binding proteins (nuclear respiratory factor [NRF] 1/2; myo-
cyte enhancer factor 2) that recruitPGC-1 topromoters and
require PGC-1 for their function. The gene encoding
PGC-1a (Ppargc1a) was among those suppressed in
MAT1-deficient hearts. However, Ppargc1a is dependent
on autoinduction by PGC-1a (Handschin et al., 2003).
Hence, downregulation of PGC-1a levels could potentially
implicate an underlying defect in PGC-1a function.
To test this, we examined the impact of acutely deleting
MAT1 on the promoters of two metabolic genes, Cycs and
Atp5b, that were downregulated in MAT1-deficient hearts
(Table 1) and have well-characterized ERR-responsive el-
ements as targets for coactivation by PGC-1a (Schreiber
et al., 2004). In the MEF cell background, exogenous
PGC-1a activated both promoters, coexpressed ERRa
further enhanced induction, and loss of MAT1 impaired
the PGC-1a-dependent transcription of both reportersCell M(Figures 4C and 4D). Consistent with the preferential ex-
pression of PGC-1a in tissues like striated muscle with
high oxidative metabolism (Knutti et al., 2000), endo-
genous PGC-1a was not detected in MEFs by western
blotting (data not shown), and deleting MAT1 had no effect
on promoter activity unless PGC-1a was supplied. This
defect in PGC-1a’s ability to induce the Atp5b and Cycs
promoters suggests that MAT1 might underlie its function
as a coactivator. Indeed, MAT1 was required for PGC-1a-
dependent coactivation of PPARa using a multimerized
PPARa response element, forced expression of PPARa
plus RXRa, and oleic acid as a PPARa agonist (Figure 4E).
Absence of MAT1 also disrupted PGC-1a-dependent
coactivation of ERRa assayed under even more reduc-
tionist conditions using the GAL4 DNA-binding domain
(DBD) fused with the ERRa ligand-binding domain (LBD)
to drive a GAL4-responsive reporter (Figure 4F). The
GAL4-ERRa chimera had no activity in the absence of
supplemental PGC-1a. PGC-1a augmented transcription
via the LBD 5-fold, and coactivation by PGC-1a was
strictly contingent on endogenous MAT1. Thus, deleting
MAT1 crippled the coactivation of both PPARa and
ERRa by PGC-1a. Likewise, PGC-1b failed to transacti-
vate ERRa in the MAT1-deficient cells (Figure 4G).
To exclude defective interaction with nuclear receptors
as the basis for defective function, we tested whether
MAT1 was required for transcription when PGC-1 wasetabolism 5, 129–142, February 2007 ª2007 Elsevier Inc. 135
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MAT1 Is Required for Transactivation by PGC-1Figure 4. MAT1 Is Required for Transcriptional Activity of PGC-1-Family Proteins
MEFs from wild-type and MAT1F/F mice were transduced with Ad.Cre and then cultured for 72 hr before plasmid transfection.
(A) Expression vectors for RARa and its partner RXRa were cotransfected with RARE-tk-luc, containing two copies of the retinoic response element
upstream of the minimal thymidine kinase promoter, and 12 hr later, cells were stimulated with t-RA (106 M) for 24 hr. The known dependence of RAR
on Cdk7 (Keriel et al., 2002) was confirmed, as a positive control for the subsequent experiments.
(B) Lack of MAT1 did not affect three irrelevant promoters, Fos, Hsp70, and CMV (pRL-CMV).
(C and D) MAT1 is required for activation of the ATP synthase b and cytochrome c promoters by PGC-1a. Reporter genes were transfected in the
absence or presence of expression vectors for PGC-1a and supplemental ERRa, and luciferase activity was measured 48 hr after transfection.
Results are shown for each reporter gene relative to those in vector-transfected, wild-type control cells.
(E) MAT1 is required for PGC-1a-dependent coactivation of PPARa. PPAR(PPRE)3-tk-luc was cotransfected with expression vectors for PPARa and
RXRa in the absence or presence of PGC-1a, and 12 hr later, cells were incubated with 250 mm oleic acid for 24 hr. Data are expressed relative to
wild-type cells that did not receive PGC-1a.
(F) MAT1 is required for PGC-1a-dependent coactivation of ERRa. The GAL4-responsive reporter pGK1 was cotransfected with expression vectors
for the GAL4 DBD or a fusion of ERRa LBD to the GAL4 DBD in the presence or absence of PGC-1a. Data are expressed relative to basal activity of
GAL4 DBD in wild-type cells.136 Cell Metabolism 5, 129–142, February 2007 ª2007 Elsevier Inc.
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MAT1 Is Required for Transactivation by PGC-1tethered to DNA directly, as a GAL4 DBD fusion protein
(Figures 4H and 4I). In wild-type cells, GAL4 DBD-PGC-
1a markedly activated the GAL4-responsive reporter.
Lack of MAT1 blunted this to just one-third of the activity
in wild-type cells (Figure 4H).
Mutation of PGC-1a at L2 and L3 of the LXXLL motif al-
lows one to test more specifically the intrinsic transactiva-
tion function of GAL4 DBD-PGC-1a since nuclear recep-
tors and a key repressor, p160 myb-binding protein, are
no longer bound (Knutti et al., 2001; Huss et al., 2002;
Fan et al., 2004). As expected, PGC-1a L2/3A showed
greater transcriptional activity than wild-type PGC-1a,
and loss of MAT1 attenuated transactivation by this form
of PGC-1a to the same degree as for wild-type PGC-1a
(Figure 4H).
Transactivation by GAL4 DBD-PGC-1bwas likewise de-
fective in MAT1-deficient cells (Figure 4I), concordant with
the defect shown for coactivation of ERRa by PGC-1b
(Figure 4G). In summary, both PGC-1 family members re-
quire MAT1. Loss of MAT1 had no effect on a GAL4 control
protein fused to the VP16 activation domain (Figure 4J).
Loss of MAT1 did not impair the levels of virally delivered
PGC-1a, PGC-1b, and PPARa (Figure 4K), implicating in-
terference with function, not protein accumulation.
Because the studies in MEFs elicited functional defects
chiefly when supplemental PGC-1 was supplied (and not
under basal conditions), corroborative experiments were
done to measure MAT1-dependent expression of endog-
enous transcripts under these same circumstances
(Figure 5A). Endogenous PGC-1awas 100-fold less abun-
dant in MEFs than in 4-week-old cardiac muscle, whereas
viral gene delivery produced levels comparable to those in
cardiac cells. In agreement with Figure 4, lack of MAT1 did
not affect basal expression of representative PGC-1-
dependent genes (Cycs, Atp5b, Tfam, and Pdk4) but se-
lectively impaired their activation when PGC-1a was
raised. This difference is consistent with two possibilities.
More simply, basal expression of these genes might be in-
dependent of PGC-1. Alternatively, it might require basal
levels of PGC-1, with MAT1 necessary only at higher
PGC-1 abundance (as in cardiac muscle and transduced
MEFs). Absence of MAT1 did not affect Myc (an irrelevant
control) or the PGC-1 target Nrf1, which can be sustained
even if PGC-1a and PGC-1b are underexpressed
(McClure et al., 2005).
ERRa-VP16 Rescues Gene Expression and Survival
in MAT1-Deficient Cells
Next, we sought to determine whether one or more
requirements for MAT1 might be overcome using viral
delivery of an ERRa fusion protein that supplants the
need for PGC-1 by incorporating the VP16 activation do-Cell Mmain (Schreiber et al., 2004). Unlike PGC-1a (Figure 5A),
ERRa-VP16 induced Cycs, Atp5b, and Tfam to the same
degree in wild-type and MAT1-deficient cells (Figure 5B).
Neither ERRa nor the VP16 activation domain alone had
any effect.
Mice with heart-specific disruption of MAT1 develop
lethal apoptotic cardiomyopathy. To address a potential
transcriptional basis for apoptosis, we prepared cultured
cardiomyocytes from MAT1F/F mice and ablated MAT1
in culture by adenoviral expression of Cre. To increase
the baseline prevalence of apoptosis, the cells were incu-
bated in glucose-free medium containing 3 mM 2-deoxy-
glucose. At 16 hr, apoptosis was determined by caspase-
3 activity, caspase-3 cleavage, PARP cleavage, and
TUNEL staining (Figure 5C). For each indicator, apoptosis
was largely prevented by ERRa-VP16.
MAT1 Binds PGC-1 In Vitro and In Vivo
A potential explanation for the selective dependence of
PGC-1-regulated genes on MAT1 is that MAT1 might in-
teract physically with PGC-1. PGC-1a was expressed in
reticulocyte lysates and examined for binding to GST-
MAT1 versus GST-PPARg, a positive control (Figure 6A).
PGC-1a bound PPARg as expected and MAT1 as pre-
dicted. Little or no interaction was seen using an alterna-
tive nuclear receptor coactivator (Ncoa2/SRC2/TIF2/
GRIP1) or GST alone. In vitro-translated PGC-1b also
bound MAT1 (Figure 6A). Furthermore, in HeLa cells, ec-
topically expressed PGC-1a interacted with endogenous
MAT1, as shown by immunoprecipitation (Figure 6B).
As a third test of the MAT1/PGC-1 interaction, in vitro-
translated PGC-1a was incubated with HepG2 nuclear
extract, MAT1 was immunoprecipitated, and associated
[35S]PGC-1a was monitored (Figure 6C). PGC-1a was re-
covered by precipitation of endogenous MAT1 or endog-
enous Cdk7. To ascertain whether Cdk7 interacts with
PGC-1a directly or via associated MAT1, Cdk7 and cyclin
H were expressed as 35S-labeled proteins and examined
for ability to bind GST-MAT1. Under these conditions,
PGC-1a bound Cdk7, but not cyclin H (Figure 6D), sug-
gesting that PGC-1 a interacts with the heterotrimeric
CAK complex through both MAT1 and Cdk7.
DISCUSSION
The Cdk7/cyclin H/MAT1 complex is activated in cardiac
hypertrophy and end-stage heart failure (Sano et al.,
2002, 2004) and has postulated roles in mammals as the
kinase component of TFIIH (Zurita and Merino, 2003).
However, its potential function may vary with context
(Rossi et al., 2001; Korsisaari et al., 2002) and was alto-
gether conjectural for the heart. Here, we deleted MAT1(G) MAT1 is required for PGC-1b-dependent coactivation of ERRa. Transfections were performed and analyzed as in (F), except that PGC-1bwas used.
(H and I) MAT1 is required for the transcriptional activity of PGC-1a and PGC-1b as GAL4 DBD fusion proteins. pGK1 was cotransfected with expres-
sion plasmids for GAL4 DBD, GAL4-PGC-1a, GAL4-PGC-1a (L2/3A mutant), or PGC-1a as shown. Data are expressed relative to the basal activity of
GAL4 DBD in wild-type cells.
(J) MAT1 is dispensable for transactivation by GAL4-VP16.
(K) Loss of MAT1 does not interfere with expression of the exogenous PGC-1a, PGC-1b, and PPARa proteins.etabolism 5, 129–142, February 2007 ª2007 Elsevier Inc. 137
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MAT1 Is Required for Transactivation by PGC-1Figure 5. MAT1 Is Required for Expression of PGC-1-Dependent Transcripts and Resistance to Apoptosis
(A) Control (MAT1+/+; Ad.Cre) and MAT1-deficient (MAT1F/F; Ad.Cre) MEFs were prepared as in Figure 3 and subjected to viral delivery of PGC-1a
versus LacZ. Levels of the indicated transcripts were determined 48 hr later by real-time qRT-PCR. n = 3; *p < 0.05.
(B) Control and MAT1-deficient MEFs were subjected to viral delivery of LacZ, ERRa, VP16, or ERRa-VP16. Gene expression was analyzed as in (A).
n = 3; *p < 0.05 versus LacZ.
(C) ERRa-VP16 rescues MAT1-deficient cardiomyocytes from apoptosis caused by 2-deoxyglucose (DOG). n = 6; *p < 0.05 versus 2-DOG ();
yp < 0.05 versus 2-DOG (+).using a Cre/lox system that is active in embryonic myocar-
dium. MAT1 was required to achieve normal levels of
Cdk7 and cyclin H protein in cardiac muscle and to recruit
the kinase complex to core components of TFIIH. Deleting138 Cell Metabolism 5, 129–142, February 2007 ª2007 ElsevierMAT1 in myocardium severely impaired Cdk7 activity both
as a free heterodimer and as a part of TFIIH. Heart-specific
loss of MAT1 precipitated mitochondrial abnormalities,
myocyte apoptosis, and heart failure, best ascribed toInc.
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MAT1 Is Required for Transactivation by PGC-1Figure 6. MAT1 and Cdk7 Interact Physically with PGC-1
(A) PGC-1 proteins and TIF2/Ncoa2 (used as a negative control) were produced by in vitro transcription and translation and were then incubated with
GST-MAT1 and visualized by autoradiography. Binding of PGC-1a to GST-PPARg is shown for comparison as a positive control, and to GST alone
(overexposed intentionally) as a negative control. Both PGC-1a and PGC-1b bound to GST-MAT1.
(B) Transfected PGC-1a coimmunoprecipitates endogenous MAT1 in HeLa cells. Upper row: complexes were recovered using antibody to the FLAG
epitope tag, and MAT1 was visualized by western blotting. Lower row: western blotting for FLAG-tagged PGC-1a and Cdk9 (used as the irrelevant
control).
(C) PGC-1a produced by in vitro transcription and translation was added to HepG2 cell nuclear extracts and coprecipitated using antibodies to
endogenous MAT1 or Cdk7 and protein A-Sepharose.
(D) Cdk7 and cyclin H produced by in vitro transcription and translation were incubated with GST-PGC-1a. Binding of Cdk7 to PGC-1awas visualized
by autoradiography.a functional defect in transcriptional coactivation by
PGC-1-family proteins.
As inferred for fission yeast and flies (Schwartz et al.,
2003; Lee et al., 2005), our results support the necessity
for MAT1 in the transcription of a specific subset of genes.
At 2 weeks, few changes were evident among the 40,000
transcripts surveyed in cardiac muscle lacking MAT1,
consistent with other evidence that MAT1 can be superflu-
ous to RNAPII-dependent transcription in mammalian
cells (Korsisaari et al., 2002). Conditional ablation of
MAT1 unmasked a requirement for this protein in postna-
tal myocardium. The lethal apoptotic cardiomyopathy en-
suing after birth resembles—albeit occurring sooner—the
degenerative phenotype caused by deleting MAT1 in
Schwann cells (Korsisaari et al., 2002). The varying cata-
strophic phenotypes in MAT1 CKO mice, depending on
which cells express Cre, might derive from the respective
promoter-specific factors that are targets for Cdk7/cyclin
H/MAT1 beyond just modulation of RNAPII.
The requirement for MAT1 in cardiac mitochondrial me-
tabolism, detected by genome-wide expression profiling,
prompted us to test systematically whether MAT1 is criti-
cal for the transcriptional network regulating metabolicCell Mgene expression (Puigserver and Spiegelman, 2003; Kelly
and Scarpulla, 2004). Cardiac metabolic genes are regu-
lated by multiple nuclear receptors, especially the fatty-
acid-activated PPARs and ERRs: the cardiac-enriched
coactivators, PGC-1a and PGC-1b, are tethered to DNA
by these receptors and thereby activate transcription.
Supporting the possibility that this axis is a critical target
of MAT1, we showed that MAT1 is instrumental to the tran-
scriptional activity of both PGC-1a and PGC-1b using viral
delivery of Cre for acute deletion ofMAT1 in cultured cells.
Because MAT1 was even required for the function of a
PGC-1a mutation that no longer binds nuclear receptors
and no longer binds the endogenous repressor p160
myb-binding protein, we infer that MAT1 regulates the
transcriptional activity of PGC-1 by mechanisms indepen-
dent of these two known partners. The physical interaction
of PGC-1awith MAT1 itself suggests a likely role for MAT1
in recruiting TFIIH to PGC-1 and its gene targets. Given the
interaction of PGC-1a with Cdk7 as well, it remains to be
determined whether PGC-1 is phosphorylated by Cdk7
or, perhaps more simply, whether binding of Cdk7 to
PGC-1 helps direct the known phosphorylation of nuclear
receptors by Cdk7.etabolism 5, 129–142, February 2007 ª2007 Elsevier Inc. 139
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MAT1 Is Required for Transactivation by PGC-1The existence of an autoregulatory amplification loop
whereby PGC-1a expression depends on PGC-1a func-
tion (Handschin et al., 2003) likely contributes to this factor
and its targets being especially sensitive to inhibitory
perturbations. A concerted effect on the activity of both
PGC-1 proteins is a plausible explanation for the greater
severity of the MAT1-deficient phenotype versus the
milder baseline abnormalities in cardiac metabolism pro-
duced by deleting PGC-1a or PGC-b alone (Arany et al.,
2005; Leone et al., 2005; Lelliott et al., 2006), although
this prediction remains to be tested by a combined dele-
tion. In the present study, moreover, the expression of
both Ppargc1a and Ppargc1b was progressively reduced
in MAT1-deficient hearts, potentially compounding the
functional deficiency of these factors and contributing to
evolution of the cardiac-lethal phenotype. Genetic redun-
dancy of PGC-1a and PGC-1b has been demonstrated
directly for mitochondrial biogenesis and respiration in
brown fat (Uldry et al., 2006) but has not yet been proven
for the heart. Notably, however, even deleting just PGC-1a
markedly predisposes the mouse heart to fail (Arany et al.,
2006).
EXPERIMENTAL PROCEDURES
Mouse Models
To create the cardiac-specific MAT1 CKO, MAT1F/F mice (Korsisaari
et al., 2002) and cardiac-specific aMHC-Cre ‘‘deleter’’ mice (Gaussin
et al., 2002) were bred as described in the Results. For all compari-
sons, the CKO genotype was aMHC-Cre+/0;MAT1F/F and the littermate
control was aMHC-Cre+/0;MAT1F/+. Cardiac-specific expression of
MAT1, cyclin H, and Cdk7 was achieved using the 5.5 kb mouse
aMHC promoter from J. Robbins (Cincinnati Children’s Hospital Med-
ical Center).
Western Blotting and Immunoprecipitation
See Supplemental Data. Immunocomplex kinase assays were per-
formed using GST-CTD, GST-Cdk2, or histone H1 as substrate
(Sano et al., 2002). Complexes were resolved by SDS-PAGE, phos-
phorylation was visualized by autoradiography, and western blotting
was performed using the identical lysates. Coimmunoprecipitation
and GST pull-down assays were performed essentially as described
(Shimizu et al., 2005).
Adenoviruses and Cell Culture
Viral vectors were generated using the AdEasy system (He et al.,
1998). Adenoviruses encoding PGC-1a, ERRa, VP16, and ERRa-
VP16 were previously reported (Sano et al., 2002; Herzog et al.,
2006), and virus encoding Cre was provided by F. Graham (Anton
and Graham, 1995).
MEFs were obtained from wild-type and MAT1F/F embryos at E13.5
and were cultured in Dulbecco’s modified Eagle’s medium with 10%
fetal bovine serum. Cardiomyocytes from neonatal MAT1F/F mice
were prepared and transduced essentially as described (Sano et al.,
2002, 2004). The multiplicity of infection used was 200 (Cre and
PGC-1a) or 100 (ERRa, VP16, and ERRa-VP16) for MEFs and 20 for
cardiomyocytes (Sano et al., 2004). Cells were infected with adenovi-
rus for 6 hr. Myocytes were cultured for an additional 18 hr and treated
with 3 mM 2-deoxyglucose in glucose-free medium (Kaiser et al.,
2004). Apoptosis was monitored by caspase-3 activation and TUNEL
staining (Sano et al., 2004).140 Cell Metabolism 5, 129–142, February 2007 ª2007 ElsevierGene Expression
Genome-wide profiles were obtained using MG U74Av2 arrays (Affy-
metrix), and selected genes were assayed by quantitative RT-PCR.
See Supplemental Data.
Mitochondrial Enzyme and Respiration Assays
See Supplemental Data.
Glucose and Fatty-Acid Oxidation
Hearts of 3.5-week-old CKO and control mice were perfused retro-
gradely in the Langendorff mode (Goodwin et al., 1998) at a perfusion
pressure of 70 cm H2O and paced at 9 Hz. Stability of the preparation
was ascertained by real-time oxygen consumption and coronary flow.
Glucose and oleate oxidation were determined as described (Goodwin
et al., 1998).
Luciferase Reporter Assays
Expression vectors (0.2 mg), firefly luciferase reporter genes (0.2 mg),
and a constitutive Renilla luciferase control (pRL-CMV, Promega;
50 ng) were cotransfected using Effectene (QIAGEN) (see Supplemen-
tal Data). Luciferase activity was determined 48 hr after transfection. All
transfections comprise three or more independent experiments, each
performed in duplicate.
Statistical Analyses
Data are reported as mean ± SEM. Comparisons were analyzed by
ANOVA using a significance level of p < 0.05.
Supplemental Data
Supplemental Data include Supplemental Experimental Procedures,
Supplemental References, two figures, and two tables and can be
found with this article online at http://www.cellmetabolism.org/cgi/
content/full/5/2/129/DC1/.
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